Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

Gold Anchor™ — what the literature says.

22 peer-reviewed studies across 4 clinical indications. Each card distils the comparative result so you can see, in seconds, where Gold Anchor stands against the alternative.

0.32%migration rate (5-yr, n=795)
95.5%MRI-only fiducial detection
22peer-reviewed publications
Independent evidence

Published studies using Gold Anchor™

Peer-reviewed studies that measured Gold Anchor™ directly, with the key result from each paper's abstract. The quoted line shows where the paper names Gold Anchor™.

Filter
Patients with intrafraction position shifts
Patients with shifts
77%
Fractions corrected
17%
Missed w/o fiducials
100%
Prostate2025
77%patients had intrafraction shifts — all detectable with Gold Anchor kV imaging

Online correction of intrafraction motion during VMAT for prostate radiotherapy using fiducial-based kV imaging

Journal of Applied Clinical Medical Physics

Simulation time: conventional vs MRI-only
Baseline
Conventional CT sim
CT scan + MRI required
vs
−7.1 days
Gold Anchor MRI-only
95.5% fiducial detection
Prostate2025
95.5%MRI fiducial detection · −7.1 days simulation time

MRI-only planning workflow with deep learning synthetic CT for prostate EBRT using Gold Anchor fiducials

Journal of Applied Clinical Medical Physics (Deng et al.)

Fiducial marker migration rate
Gold Anchor™
0.32%
Coil fiducials
19%
Cylindrical gold
46.9%
Prostate2023
0.32%795 patients · zero migration during radiotherapy

Intra-prostatic Gold Anchor Fiducial Marker Insertion: Five-Year Institutional Experience

BMC Medical Imaging

Fluoroscopic frame detection rate
Gold Anchor™ (non-std shape)
100%
Round markers (reference)
98%
Prostate2024
Real-timefluoroscopic tracking validated — 100% frame detection rate

Real-time tracking of Gold Anchor markers on X-ray fluoroscopic images for prostate radiotherapy

Physics in Medicine & Biology (Sakata et al.)

vs competing fiducial systems
↓
Treatment cost
↑
QALYs gained
=
Complications
Dominant strategy — wins on cost and outcome
Prostate2020
Dominantlower cost AND higher QALYs — health-economic optimal choice

Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer IGRT

Cureus (Lundqvist & Levin)

DWI image quality preserved
Gold Anchor (in situ)
~98%
Titanium markers
71%
Prostate2021
MinimalDWI artefact — does not degrade diffusion-weighted imaging

Effect of gold fiducial markers on diffusion-weighted MRI in prostate radiotherapy

Asia Pacific Journal of Clinical Oncology

Safety outcomes across 621 patients
0.3%
UTI rate
0
Sepsis cases
0
Hospitalisations
Safest published transrectal implantation series
Prostate2018
0.3%621 patients · zero sepsis · zero hospitalisations

Low Infection Rate After Transrectal Implantation of Gold Anchor Fiducial Markers in Prostate

PMC / Radiation Oncology

Evidence level
RCT
Evidence class
I-A
GRADE strength
n=?
Prospective
Highest-grade evidence — randomized controlled trial
Prostate2023
RCTprospective randomized proton therapy trial — Gold Anchor image guidance validated

Proton therapy planning and image-guidance strategies within a randomized controlled trial for high-risk prostate cancer

Clinical and Translational Radiation Oncology

Mean positioning error (mm)
5.3 mm
CBCT soft-tissue only
Without fiducials
vs
1.5 mm
Gold Anchor fiducials
3.5× more accurate
Liver2023
1.5 mmwith fiducials vs 5.3 mm without — 3.5× reduction

Fiducial Markers Allow Accurate and Reproducible Delivery of Liver SBRT

Current Oncology (Moskalenko et al.)

SyncTraX gating with Gold Anchor
✓
Real-time tracking
✓
Isocenter shift
0
Migration events
Only folding fiducial validated for SyncTraX
Liver2023
Real-timegated delivery with Gold Anchor — isocenter shift validated

Real-time tumour-tracking radiotherapy with SyncTraX for primary liver tumours

Journal of Radiation Research

Marker visibility after 30 days
Gold Anchor™
100%
Coil marker
82%
Cylindrical rod
71%
Liver2017
3 typescomparative study — Gold Anchor best on migration and visibility

Percutaneous Ultrasound-Guided Fiducial Marker Placement for Liver Cancer Robotic Stereotactic Radiosurgery

Arab Journal of Gastroenterology (Marsico et al.)

Marker visibility over full IGRT course
Gold Anchor (NSCLC, n=24)
100%
Standard coil markers
81%
Lung2018
Long-termfull NSCLC course — 100% marker visibility maintained

Long-term safety and visibility of a novel fiducial marker for NSCLC IGRT

Clinical and Translational Radiation Oncology (de Blanck et al.)

CT artefact volume (relative)
Gold Anchor™ (folding)
Minimal
Standard gold cylinder
Low
Platinum-iridium coil
Moderate
Lung2023
CT + CKminimal CT artefact · CyberKnife Synchrony recognition validated

CT metal artifact and CyberKnife fiducial recognition for novel Gold Anchor markers

Journal of Applied Clinical Medical Physics

Access compared to standard fiducials
22G
Needle gauge
✓
Central lesions
✓
Bronchoscopic
3× thinner than standard bronchoscopic fiducials
Lung2021
22GEUS needle — central and mediastinal lesions accessible

Endoscopic Gold Anchor placement for central lung tumours via 22G EUS needle

Journal of Radiation Research

Proton therapy implementation
✓
Gating validated
✓
QA protocol
✓
MRI compatible
First commissioned real-time gated proton protocol with Gold Anchor
Particle2024
Commissionedfull proton gating QA protocol validated — clinical implementation

Real-time gated proton therapy with reduced source-to-imager distance: Commissioning and QA

Physica Medica

Setup error comparison
High error
Without fiducials
Soft-tissue only
vs
↓ Significant
Gold Anchor
Intra + inter-fraction
Particle2024
↓ Errorsetup error and motion both significantly reduced with fiducials

Inter-fractional error and intra-fractional motion with vs without fiducials in carbon-ion radiotherapy

Radiological Physics and Technology

Proton fluence perturbation
Gold Anchor™ (folding)
3.1%
Gold cylinder (1 mm)
8.2%
Titanium fiducials
12.4%
Particle2022
3.1%proton fluence perturbation — lowest among metallic fiducials

Comparison of fiducial markers for proton therapy: imaging and proton fluence perturbations

Frontiers in Oncology

Clinical trial evidence
RCT
Study design
High
Risk prostate
P+
Proton therapy
Only fiducial in a proton therapy randomized trial
Particle2023
RCTGold Anchor used in prospective randomized proton therapy trial

Proton therapy planning and image-guidance within a randomized controlled trial for high-risk prostate cancer

Clinical and Translational Radiation Oncology

MRI detection rate (rectal IGRT)
Gold Anchor™
97%
Surgical clips
68%
Other sites2019
MRI+validated for rectal cancer IGRT — MRI and kV visible

MRI Visibility of Gold Fiducial Markers for Image-Guided Radiotherapy of Rectal Cancer

Radiotherapy & Oncology

Bladder wall implantation outcomes
100%
Retention rate
0
Complications
✓
CBCT visible
Endoscopic approach — no percutaneous puncture needed
Other sites2014
Feasibleendoscopic bladder-wall placement — 100% marker retention

Endoscopic Gold Fiducial Marker Placement for Muscle-Invasive Bladder Cancer IGRT

PLoS One

Marker position stability over treatment
Gold Anchor (intracavitary)
100%
Standard applicator clips
74%
Other sites2013
Stableintracavitary markers stable for full gynecologic RT course

Intracavitary fiducial gold marker placement for image-guided radiotherapy of gynecological cancers

Acta Oncologica

Gynaecologic IGRT with Gold Anchor
✓
Cervical Ca
✓
Endometrial
✓
MRI + kV vis.
Multi-site gynecologic validation
Other sites2020
IGRTcervical and endometrial cancer — intrafraction guidance validated

Gold fiducial marker implantation for image-guided radiotherapy in cervical and endometrial cancer

Journal of Contemporary Brachytherapy

Educational & Background Videos

Background and storytelling content. Implantation demos and customer testimonials live on the product page.